Older FLT3 inhibitors, such as midostaurin, have limited efficacy as single-agent therapy in patients with FLT3mut+ AML, possibly related to their relatively limited potency in vivo [9,10]. This evidence concerns the gene FLT3 and acute myeloid leukemia.